Scholar Rock Holding Corporation
SRRK$5.20B
Mid CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaCAMBRIDGE128 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Nov 1, 2026
33wMarket Overview
Stock performance and key metrics
SRRK News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
Apitegromab
Spinal Muscular Atrophy
Tirzepatide
Overweight and Obesity
SRK-015
Spinal Muscular Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Apitegromab | Phase 3 | Spinal Muscular Atrophy | - | - |
Tirzepatide | Phase 2 | Overweight and Obesity | - | - |
SRK-015 | Phase 2 | Spinal Muscular Atrophy | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply